Abstract
Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Current Pharmaceutical Biotechnology
Title: The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems
Volume: 6 Issue: 1
Author(s): O. Kayser, A. Lemke and N. Hernandez-Trejo
Affiliation:
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Abstract: Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Export Options
About this article
Cite this article as:
Kayser O., Lemke A. and Hernandez-Trejo N., The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems, Current Pharmaceutical Biotechnology 2005; 6 (1) . https://dx.doi.org/10.2174/1389201053167158
DOI https://dx.doi.org/10.2174/1389201053167158 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era
Current Drug Metabolism Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan’s Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea
Current Cancer Drug Targets The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Humanized SCID Mice Models of SLE
Current Pharmaceutical Design Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Calcium Phosphate System for Gene Delivery: Historical Background and Emerging Opportunities
Current Pharmaceutical Design Imaging with Raman Spectroscopy
Current Pharmaceutical Biotechnology The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application
Combinatorial Chemistry & High Throughput Screening The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry New Synthesis of Isoindolo[2,1–b]isoquinolines. Preparation and Aqueous Bioavailability of its Silica Nanoparticles Hybrid System
Current Organic Chemistry OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) All for Statins and Statins for All; An Update
Current Pharmaceutical Design Full Factorial Experimental Design for Development and Validation of a RP-HPLC Method for Estimation of Letrozole in Nanoformulations
Current Pharmaceutical Analysis Quality, Safety and Efficacy in the ‘Off-Label’ Use of Medicines
Current Drug Safety Gut Microbiota and Alcoholic Liver Disease
Reviews on Recent Clinical Trials Non-Pharmacological Treatment of Depressive Disorders: A Review of Evidence-Based Treatment Options
Reviews on Recent Clinical Trials